News

NeuroVive Pharmaceutical AB, a company focused on the treatment of acute conditions linked to mitochondria, recently announced that its investigational product CicloMulsion® did not meet the primary clinical endpoint in the phase III CIRCUS trial in patients who have experienced a particular type of heart attack called ST-segment elevation…

Two researchers at Glasgow Caledonian University in the United Kingdom recently published a review focused on atherosclerosis and the role of mitochondria in the regulation of macrophages (a type of white blood cell) sterol metabolism and the inflammatory responses. The review was published in the World Journal of…

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is currently conducting a Phase III clinical study (“CIRCUS”) with its lead candidate CicloMulsion® in patients with ST-segment elevation acute myocardial infarction (STEMI). Topline results are expected in this quarter, which is sooner than expected, and will determine the success of meeting…

Researchers from the Weill Cornell Medical College Brain and Mind Research Institute in White Plains, New York are studying Huntington’s disease by exploring biochemical pathways in mouse models of the disease. The team, led by Nima N. Naseri in the laboratory of Gary E. Gibson, PhD, found that an abnormal…

Previous research has revealed the importance of mitochondrial metabolism in Amyotropic Lateral Sclerosis (ALS). ALS neurodegenerative disorder is characterized by death of motor neurons (MN) in the upper motor cortex of the brain and in the lower stem and spinal cord (comprising the Central Nervous System). As far as etiological analysis…

The Mitochondrial Medicine meeting is held annually by the United Mitochondrial Disease Foundation (UMDF) concerning mitochondrial dysfunction and disease. This year, the meeting will be held in Herndon, VA and will include two sessions: the scientific and clinical meetings will take place between June 17 and 20, 2015, and family sessions will take place between June 19 and 20, 2015. On June…

Stealth BioTherapeutics (Stealth), a privately held biopharmaceutical company committed to bringing mitochondrial therapies to patients to treat both common and rare diseases, recently announced expansion of its ophthalmology program with FDA granting a Type B meeting for genetic optic neuropathies. Optic neuropathies are common to more than 20 congenital…

In a new study entitled “SARM1 activation triggers axon degeneration locally via NAD+ destruction” researchers discovered how a protein, SARM1, underlies axon degeneration in response to injury. The mechanism may one day be translated into clinical therapeutics for neurodegenerative diseases. The study was published in the journal…

Women with mitochondrial disease hold a high risk of passing their hereditary disease on to their children. This makes having a healthy child somewhat of a gamble, but a group from Salk Institute for Biological Studies is removing the risk with tiny “molecular scissors” and recently published a report in…

Courtagen Life Sciences, Inc., released several new Next Generation Sequencing tests designed to evaluate people with epilepsy and mitochondrial disease. Mitochondrial diseases are inherited or chronic illness. They can occur either at birth or may develop later, and include problems with development and cognition. They may cause poor growth, lack of coordination, weakness, pain and seizures.